Evidence map›Paper›PMID 10582872›Full record

ArticleAntimicrobial agents and chemotherapy1999

Comparison of in vitro activities of camptothecin and nitidine derivatives against fungal and cancer cells.

M Del Poeta, S F Chen, D Von Hoff, C C Dykstra, M C Wani, G Manikumar, J Heitman, M E Wall, J R Perfect

Open access · bronzeAbstract readComparative Study
In one paragraph

Article in Antimicrobial agents and chemotherapy, 1999. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
0.1field-weighted citation impact, top 59% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 72 citations in OpenAlex.

  1. Review
  2. The Therapeutic Potential of Four Main Compounds ofPharmaceuticals (Basel, Switzerland) · 2024
    Article
  3. The first report of Apiotrichum mycotoxinivorans isolation from human cerebrospinal fluid.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2024
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Natural products targeting cancer cell dependency.The Journal of antibiotics · 2021
    Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. The antifungal pipeline: a reality check.Nature reviews. Drug discovery · 2017
    Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 6 institutions in 4 countries.

M Del PoetaDepartment of Medicine, Duke University Medical Center, Durham, North Carolina 27710, USA.
S F Chen
D Von Hoff
C C Dykstra
M C Wani
G Manikumar
J Heitman
M E Wall
J R Perfect
RTI International · USInternational Drug Development · FRAuburn University · USCzech Academy of Sciences, Institute of Microbiology · CZHoward Hughes Medical Institute · USOspedali Riuniti Umberto I · IT

Funding

GENTIC &MOLECULAR BIOLOGY OF VIRULENCE IN C. NEOFORMANSR01AI028388 · NIAID · DUKE UNIVERSITY · PI PERFECT, JOHN R. · 1991 to 2004
$1.9M
Combined Peanut Oral Immunotherapy and Anti-IgE: Mechanistic StudiesR21AI094014 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI BURKS, A. WESLEY · 2011 to 2012
$415k
Genetic molecular biology of virulence in C. neoformansR56AI028388 · NIAID · DUKE UNIVERSITY · PI PERFECT, JOHN R. · 2006 to 2006
$389k
NOVEL ANTIFUNGAL DRUG TARGETS IN CRYPTOCOCCUS NEOFORMANSR01AI041937 · NIAID · DUKE UNIVERSITY · PI HEITMAN, JOSEPH · 1997 to 1999
–
NIAID NIH HHS AI 28388NIAID NIH HHS AI41937NIAID NIH HHS AI-94-014NIAID NIH HHS R01 AI028388NIAID NIH HHS R56 AI028388
6 · The paper itself

Abstract

The activities of a series of camptothecin and nitidine derivatives that might interact with topoisomerase I were compared against yeast and cancer cell lines. Our findings reveal that structural modifications to camptothecin derivatives have profound effects on the topoisomerase I-drug poison complex in cells. Although the water-soluble anticancer agents topotecan and irinotecan are less active than the original structure, camptothecin, other derivatives or analogs with substitutions that increase compound solubility have also increased antifungal activities. In fact, a water-soluble prodrug appears to penetrate into the cell and release its active form; the resulting effect in complex with Cryptococcus neoformans topoisomerase I is a fungicidal response and also potent antitumor activity. Some of the compounds that are not toxic to wild-type yeast cells are extremely toxic to the yeast cells when the C. neoformans topoisomerase I target is overexpressed. With the known antifungal mechanism of a camptothecin-topoisomerase I complex as a cellular poison, these findings indicate that drug entry may be extremely important for antifungal activity. Nitidine chloride exhibits antifungal activity against yeast cells through a mechanism(s) other than topoisomerase I and appears to be less active than camptothecin analogs against tumor cells. Finally, some camptothecin analogs exhibit synergistic antifungal activity against yeast cells in combination with amphotericin B in vitro. Our results suggest that camptothecin and/or nitidine derivatives can exhibit potent antifungal activity and that the activities of camptothecin derivatives with existing antifungal drugs may be synergistic against pathogenic fungi. These new compounds, which exhibit potent antitumor activities, will likely require further structural changes to find more selective activity against fungal versus mammalian cells to hold promise as a new class of antifungal agents.

Indexed as

Antineoplastic Agents, PhytogenicBenzophenanthridinesCamptothecinCandida albicansCryptococcus neoformansCulture MediaDrug SynergismEnzyme InhibitorsFungiHumansMelanoma, ExperimentalMicrobial Sensitivity TestsPhenanthridinesSaccharomyces cerevisiaeTopoisomerase I InhibitorsTransformation, GeneticAntineoplastic Agents, PhytogenicBenzophenanthridinesCamptothecinCulture MediaEnzyme InhibitorsnitidinePhenanthridinesTopoisomerase I Inhibitors

Identifiers

PMID10582872
PMCPMC89577
OpenAlexW1908956228

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.